Role of telomere dysfunction in cardiac failure in Duchenne muscular dystrophy

Nature Cell Biology

Volumn 15, Issue 8, 2013, Pages 895-904

  Mourkioti, Foteini ^a   Kustan, Jackie ^a   Kraft, Peggy ^a   Day, John W ^a   Zhao, Ming Ming ^b   Kost Alimova, Maria ^c   Protopopov, Alexei ^c   Depinho, Ronald A ^c   Bernstein, Daniel ^b   Meeker, Alan K ^d   Blau, Helen M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYLATED HYDROXYANISOLE; DYSTROPHIN; MANGANESE TETRAKIS (4 BENZOIC ACID)PORPHYRIN; PORPHYRIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR MORTALITY; CHROMOSOME DISORDER; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENCY; DUCHENNE MUSCULAR DYSTROPHY; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONTRACTILITY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUALITY OF LIFE; TELOMERE DYSFUNCTION;

ANIMALS; CELL SIZE; DISEASE MODELS, ANIMAL; DYSTROPHIN; HEART FAILURE; HUMANS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; MYOCYTES, CARDIAC; TELOMERE;

MUS;

EID: 84881475183     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb2790     Document Type: Article

References (58)

1. Liew, C. C. & Dzau, V. J. Molecular genetics and genomics of heart failure. Nat. Rev. Genet. 5, 811-825 (2004). (Pubitemid 39457497)
2. Hoffman, E. P., Brown, R. H. Jr & Kunkel, L. M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51, 919-928 (1987).
3. Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M. & Sweeney, H. L. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl Acad. Sci. USA 90, 3710-3714 (1993). (Pubitemid 23111437)
4. Bushby, K., Muntoni, F. & Bourke, J. P. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul. Disord. 13, 166-172 (2003). (Pubitemid 36140013)
5. Baxter, P. Treatment of the heart in Duchenne muscular dystrophy. Dev. Med. Child Neurol. 48, 163 (2006). (Pubitemid 44404258)
6. Duan, D. Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Human Mol. Genet. 15 (Spec No 2), R253-R261 (2006). (Pubitemid 44446801)
7. McNally, E. M. New approaches in the therapy of cardiomyopathy in muscular dystrophy. Annu. Rev. Med. 58, 75-88 (2007). (Pubitemid 46706502)
8. Cohn, J. N. Heart failure: future treatment approaches. Am. J. Hypertens. 13, 74S-78S (2000). (Pubitemid 30332452)
9. Cohn, R. D. et al. Angiotensin II type 1 receptor blockade attenuates TGF-β-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13, 204-210 (2007).
10. Bulfield, G., Siller, W. G., Wight, P. A. & Moore, K. J. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl Acad. Sci. USA 81, 1189-1192 (1984). (Pubitemid 14171480)
11. Bridges, L. R. The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice. J. Neurol. Sci. 72, 147-157 (1986). (Pubitemid 16125194)
12. Torres, L. F. & Duchen, L. W. The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain 110 (pt 2), 269-299 (1987). (Pubitemid 17055813)
13. Greider, C. W. & Blackburn, E. H. The telomere terminal transferase of Tetrahymena is a ribonucleoprotein enzyme with two kinds of primer specificity. Cell 51, 887-898 (1987).
14. Kipling, D. & Cooke, H. J. Hypervariable ultra-long telomeres in mice. Nature 347, 400-402 (1990).
15. Hemann, M. T. & Greider, C. W. Wild-derived inbred mouse strains have short telomeres. Nucleic Acids Res. 28, 4474-4478 (2000).
16. Lee, H. W. et al. Essential role of mouse telomerase in highly proliferative organs. Nature 392, 569-574 (1998).
17. Sacco, A. et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143, 1059-1071 (2010).
18. Bergmann, O. et al. Evidence for cardiomyocyte renewal in humans. Science 324, 98-102 (2009).
19. Blasco, M. A. et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 91, 25-34 (1997). (Pubitemid 27431310)
20. Im, W. B. et al. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Human Mol. Genet. 5, 1149-1153 (1996). (Pubitemid 26318554)
21. Emery, A. E. Population frequencies of inherited neuromuscular diseases-A world survey. Neuromuscul. Disord. 1, 19-29 (1991).
22. Finsterer, J. & Stollberger, C. The heart in human dystrophinopathies. Cardiology 99, 1-19 (2003). (Pubitemid 36206630)
23. Sanyal, S. K. & Johnson, W. W. Cardiac conduction abnormalities in children with Duchenne's progressive muscular dystrophy: electrocardiographic features and morphologic correlates. Circulation 66, 853-863 (1982). (Pubitemid 12015073)
24. Schneider, J. E. et al. Fast, high-resolution in vivo cine magnetic resonance imaging in normal and failing mouse hearts on a vertical 11.7 T system. J. Magn. Reson. Imaging 18, 691-701 (2003). (Pubitemid 37467270)
25. Flores, I. et al. The longest telomeres: a general signature of adult stem cell compartments. Genes Dev. 22, 654-667 (2008). (Pubitemid 351342437)
26. Gonzalez-Suarez, E., Samper, E., Flores, J. M. & Blasco, M. A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26, 114-117 (2000).
27. Meeker, A. K. & De Marzo, A. M. Recent advances in telomere biology: implications for human cancer. Curr. Opin. Oncol. 16, 32-38 (2004). (Pubitemid 38703469)
28. Meeker, A. K. et al. Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining. Am. J. Pathol. 160, 1259-1268 (2002). (Pubitemid 34411630)
29. Meeker, A. K. et al. Telomere shortening occurs in subsets of normal breast epithelium as well as in situ and invasive carcinoma. Am. J. Pathol. 164, 925-935 (2004). (Pubitemid 38235474)
30. Sahin, E. et al. Telomere dysfunction induces metabolic and mitochondrial compromise. Nature 470, 359-365 (2011).
31. Brown, D. A. & O'Rourke, B. Cardiac mitochondria and arrhythmias. Cardiovasc. Res. 88, 241-249 (2010).
32. Iglewski, M., Hill, J. A., Lavandero, S. & Rothermel, B. A. Mitochondrial fission and autophagy in the normal and diseased heart. Curr. Hypertens. Rep. 12, 418-425 (2010).
33. Murdoch, C. E., Zhang, M., Cave, A. C. & Shah, A. M. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc. Res. 71, 208-215 (2006).
34. Takimoto, E. et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J. Clin. Invest. 115, 1221-1231 (2005). (Pubitemid 40629040)
35. Van Empel, V. P. et al. Downregulation of apoptosis-inducing factor in harlequin mutant mice sensitizes the myocardium to oxidative stress-related cell death and pressure overload-induced decompensation. Circ. Res. 96, e92-e101 (2005).
36. Sawyer, D. B. Oxidative stress in heart failure: what are we missing? Am. J. Med. Sci. 342, 120-124 (2011).
37. Rasmussen, H. H., Hamilton, E. J., Liu, C. C. & Figtree, G. A. Reversible oxidative modification: implications for cardiovascular physiology and pathophysiology. Trends Cardiovasc. Med. 20, 85-90 (2010).
38. Kratsios, P. et al. Antioxidant amelioration of dilated cardiomyopathy caused by conditional deletion of NEMO/IKK γ in cardiomyocytes. Circ. Res. 106, 133-144 (2010).
39. Shigenaga, M. K., Gimeno, C. J. & Ames, B. N. Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc. Natl Acad. Sci. USA 86, 9697-9701 (1989). (Pubitemid 20030700)
40. Shirendeb, U. et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Human Mol. Genet. 20, 1438-1455 (2011).
41. Li, Y. et al. Cytosolic, but not mitochondrial, oxidative stress is a likely contributor to cardiac hypertrophy resulting from cardiac specific GLUT4 deletion in mice. FEBS J. (2011).
42. Sanyal, S. K., Johnson, W. W., Thapar, M. K. & Pitner, S. E. An ultrastructural basis for electrocardiographic alterations associated with Duchenne's progressive muscular dystrophy. Circulation 57, 1122-1129 (1978). (Pubitemid 8343629)
43. Finder, J. D. et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am. J. Respir. Crit. Care Med. 170, 456-465 (2004). (Pubitemid 39214623)
44. Deconinck, A. E. et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717-727 (1997). (Pubitemid 27357963)
45. Megeney, L. A. et al. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc. Natl Acad. Sci. USA 96, 220-225 (1999). (Pubitemid 29036080)
46. Rooney, J. E. et al. Severe muscular dystrophy in mice that lack dystrophin and α7 integrin. J. Cell Sci. 119, 2185-2195 (2006). (Pubitemid 43960308)
47. Grady, R. M. et al. Role for α-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell Biol. 1, 215-220 (1999). (Pubitemid 129500940)
48. Chandrasekharan, K. et al. A human-specific deletion in mouse Cmah increases disease severity in the mdx model of Duchenne muscular dystrophy. Sci. Transl. Med. 2, 42ra54 (2010).
49. Qi, L. et al. Short telomeres and ataxia-telangiectasia mutated deficiency cooperatively increase telomere dysfunction and suppress tumorigenesis. Cancer Res. 63, 8188-8196 (2003). (Pubitemid 37549467)
50. Wong, K. K. et al. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 421, 643-648 (2003).
51. Chamberlain, J. S. Duchenne muscular dystrophy models show their age. Cell 143, 1040-1042 (2010).
52. Frankel, K. A. & Rosser, R. J. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum. Pathol. 7, 375-386 (1976).
53. Esposito, L. A., Melov, S., Panov, A., Cottrell, B. A. & Wallace, D. C. Mitochondrial disease in mouse results in increased oxidative stress. Proc. Natl Acad. Sci. USA 96, 4820-4825 (1999). (Pubitemid 29214495)
54. Narula, N. et al. Adenine nucleotide translocase 1 deficiency results in dilated cardiomyopathy with defects in myocardial mechanics, histopathological alterations, and activation of apoptosis. JACC Cardiovasc. Imaging 4, 1-10 (2011).
55. Brouilette, S., Singh, R. K., Thompson, J. R., Goodall, A. H. & Samani, N. J. White cell telomere length and risk of premature myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 23, 842-846 (2003). (Pubitemid 36566175)
56. Urashima, T. et al. Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am. J. Physiol. Heart Circ. Physiol. 295, H1351-H1368 (2008).
57. McCalmon, S. A. et al. Modulation of angiotensin II-mediated cardiac remodeling by the MEF2A target gene Xirp2. Circ. Res. 106, 952-960 (2010).
58. Yin, F. C. P., Spurgeon, H. A., Rakusan, K., Myron, L. & Lakatta, W. E. G. Use of tibial length to quantify cardiac hypertrophy: application in the aging rat. Am. J. Physiol. Heart Circ. Physiol. 243, H941-H947 (1982). (Pubitemid 13169525)